The changing scene of amyotrophic lateral sclerosis

@article{Robberecht2013TheCS,
  title={The changing scene of amyotrophic lateral sclerosis},
  author={Wim Robberecht and Thomas Ernest James Philips},
  journal={Nature Reviews Neuroscience},
  year={2013},
  volume={14},
  pages={248-264}
}
Several recent breakthroughs have provided notable insights into the pathogenesis of amyotrophic lateral sclerosis (ALS), with some even shifting our thinking about this neurodegenerative disease and raising the question as to whether this disorder is a proteinopathy, a ribonucleopathy or both. In addition, these breakthroughs have revealed mechanistic links between ALS and frontotemporal dementia, as well as between ALS and other neurodegenerative diseases, such as the cerebellar atrophies… 
Amyotrophic Lateral Sclerosis 1 and Many Diseases
TLDR
There are clearly common clinical and pathologic features across all of ALS, which suggests that commonality may hold critical keys to understanding ALS.
The genetic basis of amyotrophic lateral sclerosis: recent breakthroughs
TLDR
The genetic basis of ALS is discussed, and the causal genes to three highly interrelated pathogenic mechanisms: dysproteostasis, RNA dysregulation, and axon dysfunction are linked.
The phenotypic variability of amyotrophic lateral sclerosis
TLDR
The phenotypic variability of ALS is reviewed and how it is reflected in familial and sporadic ALS, in the degree of upper and lower motor neuron involvement, in motor and extramotor involvement, and in the spectrum of ALS and frontotemporal dementia.
Genetics of Amyotrophic Lateral Sclerosis.
TLDR
Findings from ALS genetics provide new insight into therapies that target genetically distinct subsets of ALS and FTD, as well as numerous downstream pathophysiological events.
Emerging understanding of the genotype-phenotype relationship in amyotrophic lateral sclerosis.
TLDR
There are over 100 ALS-associated mutations, and importantly, several genetic mutations, including C9ORF72, SOD1, and TARDBP, have led to mechanistic insight into this complex disease.
Barriers to novel therapeutics in amyotrophic lateral sclerosis
TLDR
The prevalent barriers, including clinical and genetic variability of amyotrophic lateral sclerosis, frailty of the current mouse model and inadequateness of clinical trials, are discussed in the search for novel therapeutics.
Amyotrophic Lateral Sclerosis: Current Therapeutic Perspectives
TLDR
This chapter focuses on studies of various small pharmacological compounds targeting the proposed pathogenic mechanisms of ALS and discusses their impact on disease progression, and summarizes the progress in the non-pharmacological therapy trials in ALS.
Diagnostic Challenge and Neuromuscular Junction Contribution to ALS Pathogenesis
TLDR
A combination of further research on the NMJ parameters that are specific for this disease and laboratory tests are crucial for the early determination of specific changes in the muscle, as well as in motor neuron and the prediction of ALS progression.
The Emerging Roles of MicroRNAs in the Pathogenesis of Frontotemporal Dementia–Amyotrophic Lateral Sclerosis (FTD-ALS) Spectrum Disorders
TLDR
The authors will focus on microRNAs and review the emerging roles of these small RNAs in several aspects of FTD-ALS pathogenesis, setting the stage for further understanding of the disorder.
Amyotrophic lateral sclerosis: mechanisms and therapeutic strategies
TLDR
The evidence for the involvement of a number of different biological processes that could lead to these new therapeutic strategies and that can be translated into new therapeutic approaches are summarized.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 260 REFERENCES
Pathological TDP‐43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations
TLDR
This study investigated TDP‐43 in a larger series of ALS cases, including familial cases with and without SOD1 mutations, and identified it as the major pathological protein in sporadic ALS.
Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease
TLDR
An improved understanding of the biological processes that cause neuroinflammation will help to define its medical importance and to identify the therapeutic potential of interfering with this reaction.
Differential involvement of optineurin in amyotrophic lateral sclerosis with or without SOD1 mutations.
TLDR
Evidence is provided that optineurin is involved in the pathogenesis of sporadic ALS and non- SOD1 familial ALS, thus supporting the hypothesis that these forms of ALS share a pathway that is distinct from that of S OD1-linked ALS.
The overlap of amyotrophic lateral sclerosis and frontotemporal dementia
TLDR
Patients with frontotemporal dementia with no known diagnosis of ALS or family history of ALS were clinically and electrophysiologically assessed for the presence of ALS and two had EMG findings suggestive of denervation in one limb.
Frontotemporal dementia and motor neurone disease: Overlapping clinic-pathological disorders
TLDR
The overlap between FTD and MND is reviewed, emphasizing areas of controversy and uncertainty.
Nogo Provides a Molecular Marker for Diagnosis of Amyotrophic Lateral Sclerosis
TLDR
The alteration in Nogo expression pattern, common to sporadic and familial ALS, represents a potential diagnosis tool and points strongly to Nogo having a central role in disease.
Mutations of optineurin in amyotrophic lateral sclerosis
TLDR
It is shown that there are mutations in the gene encoding optineurin (OPTN), earlier reported to be a causative gene of primary open-angle glaucoma (POAG), in patients with ALS and these findings strongly suggest that OPTN is involved in the pathogenesis of ALS.
Widespread multiple system degeneration in a patient with familial amyotrophic lateral sclerosis
TLDR
It is considered that in this patient the underlying degenerative process of the disease had become manifested in wider areas than recognized previously during the prolonged clinical course due to respiratory support, but whether or not such widespread degeneration would occur in all patients with this disease who survive longer with the help of respiratory support awaits further studies.
TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia
TLDR
TDP-43 and FUS are promising candidates for the development of novel biomarker assays and targeted therapies because of the striking functional and structural similarities of these proteins, which imply that abnormal RNA metabolism is a pivotal event in neurodegeneration.
ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis
TLDR
The finding of seven missense mutations in 15 individuals, of whom four had familial ALS and 11 apparently 'sporadic' ALS, provides further evidence that variations in hypoxia-inducible genes have an important role in motor neuron degeneration.
...
1
2
3
4
5
...